Japan health authority warns on falsified exenatide pens
Reported from the analysis, not from a warning notice.
Certificates of analysis
Page 31 of 51 of this archive, newest first.
GL Biochem declines, for the 14th time, to name its synthesis house
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
TFC declines, for the 16th time, to name its synthesis house
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
Independent analysis puts a WWB mazdutide lot at 98.5%, against 97.3% on the certificate
The Journal submitted the sample and paid for the analysis. The vendor was told in advance.
What twenty companies say about storage, and what they have measured
Storage instructions in this market are close to uniform and almost never accompanied by the study that would justify them. Uniformity is a sign of convention, not of…
Medutest result on a Wuxi dulaglutide lot lands 2.0 points below the supplier’s figure
The supplier has not disputed the finding. It has not explained the gap either.
Why the compendial sterility test is a rejection test and nothing more
The compendial sterility test cannot demonstrate that a batch is sterile. It can only fail a batch that is grossly contaminated. Everything else is process validation.
The certificate says 2025. The vial in your hand does not say anything.
What happens to traceability when bulk material is subdivided, repackaged and relabelled two or three times before sale.
Holograms, QR codes and other things that are not verification
Reported from the analysis, not from a warning notice.
New Zealand health authority warns on falsified tirzepatide pens
Reported from the analysis, not from a warning notice.
ERP declines, for the 3rd time, to name its synthesis house
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
Independent analysis puts a SSA survodutide lot at 97.1%, against 96.4% on the certificate
The result is unremarkable. What the report omits is not.
Medutest result on a Nantong semaglutide lot lands 3.0 points below the supplier’s figure
The Journal submitted the sample and paid for the analysis. The vendor was told in advance.
The last mile is the warmest mile
The honest finding is more nuanced than the alarm: a lyophilised cake tolerates a brief warm excursion far better than a reconstituted solution does, and the trade’s real…
Independent analysis puts a QSC exenatide lot at 97.5%, against 96.7% on the certificate
The supplier has not disputed the finding. It has not explained the gap either.
Sending the same vial twice, under two names
The Journal submitted split samples from single lots to three assay services, under names unconnected to this publication, and published each method alongside each result.
Holograms, QR codes and other things that are not verification
Reported from the analysis, not from a warning notice.
TFC declines, for the 15th time, to name its synthesis house
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
Spain health authority warns on falsified dulaglutide pens
Reported from the analysis, not from a warning notice.
Everything a buyer assumes has been checked, ranked by whether it has
The absences are not concealment. They are the form the trade settled on, and no buyer has ever objected.